✦ LIBER ✦

Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)

✍ Scribed by Stein, M.; Wasserman, R.L.; Melamed, I.; Puck, J.; Gupta, S.; Engl, W.; Leibl, H.; Gelmont, D.; Schiff, R.I.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics (PK) of Human Immunoglo

✍ Rubinstein, A.; Wasserman, R.L.; Melamed, I.; Stein, M.; McCoy, B.; Engl, W.; Le 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Pharmacokinetic Analysis (PK) of Immune

✍ Leibl, H.; Wasserman, R.L.; Melamed, I.; Stein, M.; Engl, W.; Schiff, R.I.; Gelm 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Efficacy Analysis of Immune Globulin Sub

✍ Schiff, R.I.; Wasserman, R.L.; Melamed, I.; Stein, M.; Engl, W.; Leibl, H.; Gelm 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Tolerability of Human Immunoglobulin 10%

✍ Gelmont, D.; Wasserman, R.L.; Melamed, I.; Stein, M.; Rubinstein, A.; McCoy, B.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Tolerability and Efficacy of Facilitated

✍ Wasserman, R.L.; Melamed, I.; Stein, M.; Puck, J.; Gupta, S.; Engl, W.; Leibl, H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Safety and Pharmacokinetics of Facilitat

✍ Melamed, I.; Wasserman, R.L.; Stein, M.; Puck, J.; Gupta, S.; Engl, W.; Leibl, H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 39 KB